While the research does not specifically address the application of lnc-ITSN1-2 for monitoring therapeutic efficacy over time, its robust association with disease activity markers suggests that future investigations could consider its utility in evaluating patient responses to RA treatments [98]. This evidence concerns the gene ITSN1 and rheumatoid arthritis.